Abingworth, an international investment group focused on life sciences, closed its latest fund, Abingworth Bioventures VII (ABV VII), at $315m.
ABV VII, which exceeded its target of $300m, is Abingworth’s 12th fund. Its investor base include capital from endowments, foundations, fund-of-funds, family offices, healthcare corporations, insurance companies and pension plans across the US, Europe and Asia.
It invests broadly across all stages of development including early and late-stage venture deals, Clinical Co-development, VIPEs (Venture Investments in Public Equities) and public equities. Investment size per company will typically range from $15 million to $30 million.
The fund invests in life sciences companies in Europe and the US.
Recent exits include the acquisitions of Wilson Therapeutics by Alexion and of IFM Therapeutics by Bristol-Myers Squibb.
Led by Kurt von Emster and Tim Haines, Managing Partners, Abingworth has invested in 148 life science companies, leading to 65 IPOs and 46 mergers and acquisitions.
It has over $1.2 billion under management and a team of 27 at offices in London, Menlo Park (California) and Boston.